Attention! Information is for reference only!
Before taking the course, consult a doctor!
WEB SITE ONLY DIRECTORY. NOT PHARMACY! We do not sell medicines! None!

Description of the medicine: Instenon (Instenon)

Instenon * (Name of the drug company "Hafslund"

Nycomed Pharma AG.).

Combined drug containing three separate medicinal substances: hexobenzene, etamivan and etofillin.


Synonyms: Ditrimine, Dilancor, Ditrimin, Hexabendin, Ustimon.

Has spasmolytic and vasodilating activity. Moderately dilates the coronary vessels. Earlier (under the name "Dytrimin") was used as an antianginal agent, however in this respect it is inferior to modern antianginal drugs.

The drug slightly strengthens cerebral circulation and improves metabolic processes in the brain, which is the reason for its inclusion in the drug instenona.

Ethamivan (Etamivan).

N, N-Diethylamide of vanillic acid.

Synonyms: Antalerton, Sardiovanil, Sourivanil, Emivan, Romecor, Sevanil, Vendid, Vintilon and others.

By chemical structure and pharmacological action is close to the cordyamine (see). Is an analeptic. Stimulates the central nervous system, excites the respiratory and vasomotor centers.

Ethophillin (Etofillin).

Hydroxyethyl proteophile.

Synonyms: Aethorhullin, Sorhyllin N, Sordalin, Ohurhyllin, Soluphyllin, Thoostat, Thoehullin and others.

The structure and pharmacological properties are close to theophylline and diprofylline (see). Improves cerebral circulation, stimulates the vasomotor center, has a positive inotropic effect on the heart; Has also bronchodilator and a moderate degree of diuretic activity.

The combination of these three substances justifies the use of instenona for improving the functions of the brain in conditions of disturbed blood flow, ischemia and hypoxia.

The drug is proposed for use in ischemic stroke, residual events after a stroke, discirculatory encephalopathy, posttraumatic encephalopathy, vegetovascular dystonia and other manifestations of cerebrovascular insufficiency.

Assign instenon inside, intravenously and intramuscularly.

Inside take predominantly for chronic forms of cerebrovascular insufficiency for 1 dragee of forteon forte or 2 dragee instenona 2 - 3 times a day for 3 to 4 weeks.

Intentionally (or intramuscularly) is prescribed instenon mainly in acute forms of ischemia and hypoxia of the brain. Enter 1 ml (1 ampoule) 1 2 - 3 times a day for 3 - 5 days or until the clinical improvement. Intravenous administration is slow (drip). The contents of the ampoule are diluted in 200 ml of 5% glucose solution or isotonic sodium chloride solution. With rapid intravenous administration, it is possible to develop tachycardia, the appearance of headache, hyperemia of the face.

The use of instenon is contraindicated with increased intracranial pressure, intracerebral hemorrhages, epilepsy.

Form release: dragees containing 20 mg hexobendine, 50 mg etamivan and 60 mg etofillina; Dragee forte containing 60 mg of hexobendin, 100 mg etamivan and 60 mg of ethophylline; In ampoules containing 10 mg of hexobendin, 50 mg etamivan and 100 mg etofillina.